Business
BioElectronics Announces Independent Migraine Clinical Study; Migraine Prevention Using ActiPatch (Pulsed Shortwave Therapy)
BioElectronics Announces Independent Migraine Clinical Study; Migraine Prevention Using ActiPatch (Pulsed Shortwave Therapy).
About this update from Bioelectronics Corp.
[{"type":"text","content":"\n \n \n BioElectronics Announces Independent Migraine Clinical Study; Migraine Prevention Using ActiPatch (Pulsed Shortwave Therapy)\n \n \nBioElectronics Announces Independent Migraine Clinical Study; Migraine Prevention Using ActiPatch (Pulsed Shortwave Therapy)\n \n FREDERICK, MD--(Marketwired - May 30, 2017) - BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce the commencement of a clinical study investigating \"prevention of migraine\" using ActiPatch therapy. Migraine is a debilitating condition that affects more than 36 million Americans, accounting for nearly $36 billion in direct and indirect costs every year in the US alone [1]. \n Chronic pain is now widely understood to be due to central sensitization, which leads to exaggerated pain perception [2]. Migraine is no exception, since it is well known that sensitization of the trigeminovascular pain pathway can accompany migraine attacks [3]. There is early evidence that ActiPatch can help mitigate this sensitization, so this study is being conducted to determine the efficacy of ActiPatch in preventing chronic migraines. \n The study will be a randomized, double-blinded placebo controlled study to investigate the efficacy of ActiPatch in preventing migraine attacks. The study will involve 48 subjects who have been previously diagnosed with migraine. The study is scheduled to take place in two, 4-week periods. The first 4 weeks will serve as a run-in period, during which subjects receive no therapy. After a 1 week break, the subjects will receive either a placebo or active ActiPatch device to use as an intervention for 4 weeks. Each subject will use a standardized migraine diary to record the frequency, duration and severity of their migraine attacks for both 4-week periods. Full details about the study can be found at the NIH's clinical trials listing page: (https://clinicaltrials.gov/ct2/show/NCT03166046?term=migraine+actipatch&rank=1)\n The principal investigator (PI) leading the study is Dr. Barry Eppley, M.D., D.M.D., a plastic surgeon at the Indiana University Health Hospital and clinical professor at the Indiana School of Medicine. Dr. Eppley has years of experience treating migraines, and believes ActiPatch therapy holds promise. He has listed details about the clinical study, along with details on how to apply to be a partic...